Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/23/23
End: 11/30/26
Due: 11/30/27
Phase: N/A
Priority: Normal
Start: 04/29/25
End: 04/30/41
Due: 04/30/42
Phase: N/A
Priority: Normal
Start: 01/25/22
End: 10/31/27
Due: 10/31/28
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies | NCT05665062 | Synthekine | user2@example.com | None | 2023-04-23 | 2026-11-30 | 2027-11-30 | - | - | 2025-07-14 |
| A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease | NCT06544330 | Synthekine | user2@example.com | None | 2025-04-29 | 2041-04-30 | 2042-04-30 | - | - | 2025-07-14 |
| STK-012 Monotherapy and in Combination Therapy in Patients With Solid Tumors | NCT05098132 | Synthekine | user2@example.com | None | 2022-01-25 | 2027-10-31 | 2028-10-31 | - | - | 2025-07-14 |